| Title: |
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer |
| Authors: |
Ozkanli, Gulhan; Duman, Berna Bozkurt; Aydin, Dincer; Dulgar, Ozgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Baris; Inal, Ali; Iriagac, Yakup; Kalkan, Nurhan Onal; Keser, Murat; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Ozdemir, Ozlem; Turhal, Nazim Serdar; Karadurmus, Nuri; Yalcin, Bulent; Sendur, Mehmet Ali Nahit; Çakan Demirel, Burçin; Paydas, Semra; Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Acar, Ömer; Aksoy, Sercan; Baytemur, Naziyet Kose; Sahin, Elif; Cabuk, Devrim; Basaran, Gül; Guven, Deniz Can; Erdogan, Atike Pinar; Demirci, Umut; Yasar, Alper; Bayoglu, Ibrahim Vedat; Hizal, Mutlu; Gulbagci, Burcu; Paksoy, Nail; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel Oyucu; Kayikcioglu, Erkan; Aytac, Ali; Unal, Olcun Umit; Demir, Hacer; Erol, Cihan; Selcukbiricik, Fatih; Sakalar, Teoman; Sunar, Veli; Keskinkilic, Merve; Mocan, Eda Eylemer; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Uluc, Basak Oyan; Ozcelik, Melike; Hacibekiroglu, Ilhan; Aydiner, Adnan; Oksuzoglu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Aksoy, Asude; Karakas, Yusuf; Yaren, Arzu |
| Publisher Information: |
Future Medicine Ltd |
| Publication Year: |
2023 |
| Collection: |
Pamukkale University Repository / Pamukkale Üniversitesi Açık Erişim Arşivi |
| Subject Terms: |
CDK 4; 6 inhibitors; HER2-negative metastatic breast cancer; HR-positive; letrozole |
| Description: |
Article; Early Access ; Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results ; conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
Future Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/51149; WOS:000991646700001 |
| DOI: |
10.2217/fon-2022-1287 |
| Availability: |
https://hdl.handle.net/11499/51149; https://doi.org/10.2217/fon-2022-1287 |
| Rights: |
none |
| Accession Number: |
edsbas.BA24BFA2 |
| Database: |
BASE |